China to drive a weight-loss drug price war
The active ingredient semaglutide is starting to lose patent protection and China can produce GLP-1 related treatments at scale
Related reading
Indian weight-loss market becomes ‘bloodbath’ as drugmakers pile in
Consumers await cheaper generics after expiry of patent for Ozempic ingredient
US weight-loss biotech’s $600mn fund raise signals China’s role in drug trials
Clinical studies can be finished faster and cheaper than in US and provide an earlier sign of a drug’s potential
Weight-loss jabs push sugar price to five-year low
Futures price has fallen to less than half its level in late 2023 as GLP-1s reduce cravings for sweet snacks
AstraZeneca strikes $4.7bn China deal to boost weight-loss drugs pipeline
Drugmaker expands push into fast-growing market
The race to launch a pill for weight loss
Despite success with injectable drugs pharma companies are investing heavily in tablets, long considered the holy grail of…
Europe’s pharma industry risks lagging behind US and China, says German…
Boehringer Ingelheim says pricing regime hinders access to treatments as group touts liver benefits from weight-loss drug